WARRINGTON, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (Windtree or the Company), a biotechnology company focused on advancing early and late-stage...
WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (Windtree or the Company) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
WARRINGTON, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (Windtree or the Company) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an...
WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (Windtree or the Company) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
WARRINGTON, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (œWindtree or the œCompany) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (œWindtree or the œCompany) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for...
Windtree Therapeutics is heading back to the licensing well, using a familiar bucket to reel in more biobucks.
The new preclinical data further supports istaroxime clinical data from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute...
SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3 The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime...